Thus, treating breast cancer patients with an EGFR inhibitor and β-blocker is recommended because the β-blocker can reduce tumor proliferation and metastasis [49, 54]; thus, increasing the probability of a optimistic prognosis. Here, EGFR is linked to breast carcinoma.